216 related articles for article (PubMed ID: 22964035)
41. AC133 expression associated with poor prognosis in stage II colorectal cancer.
Ying X; Wu J; Meng X; Zuo Y; Xia Q; Chen J; Feng Y; Liu R; Li L; Huang W
Med Oncol; 2013 Mar; 30(1):356. PubMed ID: 23322518
[TBL] [Abstract][Full Text] [Related]
42. Copper-64-diacetyl-bis (N4-methylthiosemicarbazone) accumulates in rich regions of CD133+ highly tumorigenic cells in mouse colon carcinoma.
Yoshii Y; Furukawa T; Kiyono Y; Watanabe R; Waki A; Mori T; Yoshii H; Oh M; Asai T; Okazawa H; Welch MJ; Fujibayashi Y
Nucl Med Biol; 2010 May; 37(4):395-404. PubMed ID: 20447549
[TBL] [Abstract][Full Text] [Related]
43. High CD133 expression in the nucleus and cytoplasm predicts poor prognosis in non-small cell lung cancer.
Huang M; Zhu H; Feng J; Ni S; Huang J
Dis Markers; 2015; 2015():986095. PubMed ID: 25691807
[TBL] [Abstract][Full Text] [Related]
44. Differential role of CD133 and CXCR4 in renal cell carcinoma.
D'Alterio C; Cindolo L; Portella L; Polimeno M; Consales C; Riccio A; Cioffi M; Franco R; Chiodini P; Cartenì G; Mirone V; Longo N; Marra L; Perdonà S; Claudio L; Mascolo M; Staibano S; Falsaperla M; Puglisi M; Martignoni G; Ficarra V; Castello G; Scala S
Cell Cycle; 2010 Nov; 9(22):4492-4500. PubMed ID: 21127401
[TBL] [Abstract][Full Text] [Related]
45. Frequency and pattern of expression of the stem cell marker CD133 have strong prognostic effect on the surgical outcome of colorectal cancer patients.
Takahashi S; Kamiyama T; Tomaru U; Ishizu A; Shida T; Osaka M; Sato Y; Saji Y; Ozaki M; Todo S
Oncol Rep; 2010 Nov; 24(5):1201-12. PubMed ID: 20878111
[TBL] [Abstract][Full Text] [Related]
46. CD133 expression is correlated with poor prognosis in colorectal cancer.
Kashihara H; Shimada M; Kurita N; Iwata T; Sato H; Kozo Yoshikawa ; Higashijima J; Chikakiyo M; Nishi M; Matsumoto N
Hepatogastroenterology; 2014 Sep; 61(134):1563-7. PubMed ID: 25436343
[TBL] [Abstract][Full Text] [Related]
47. Expression of CD133 correlates with differentiation of human colon cancer cells.
Feng HL; Liu YQ; Yang LJ; Bian XC; Yang ZL; Gu B; Zhang H; Wang CJ; Su XL; Zhao XM
Cancer Biol Ther; 2010 Feb; 9(3):216-23. PubMed ID: 20023382
[TBL] [Abstract][Full Text] [Related]
48. Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer.
Wang Q; Chen ZG; Du CZ; Wang HW; Yan L; Gu J
Histopathology; 2009 Sep; 55(3):284-93. PubMed ID: 19723143
[TBL] [Abstract][Full Text] [Related]
49. Response to stress in early tumor colonization modulates switching of CD133-positive and CD133-negative subpopulations in a human metastatic colon cancer cell line, SW620.
Hsu CS; Tung CY; Yang CY; Lin CH
PLoS One; 2013; 8(4):e61133. PubMed ID: 23577199
[TBL] [Abstract][Full Text] [Related]
50. Identification of Endothelin-1 and NR4A2 as CD133-regulated genes in colon cancer cells.
Puglisi MA; Barba M; Corbi M; Errico MF; Giorda E; Saulnier N; Boninsegna A; Piscaglia AC; Carsetti R; Cittadini A; Gasbarrini A; Sgambato A
J Pathol; 2011 Oct; 225(2):305-14. PubMed ID: 21826669
[TBL] [Abstract][Full Text] [Related]
51. Expression of CD133-1 and CD133-2 in ovarian cancer.
Ferrandina G; Bonanno G; Pierelli L; Perillo A; Procoli A; Mariotti A; Corallo M; Martinelli E; Rutella S; Paglia A; Zannoni G; Mancuso S; Scambia G
Int J Gynecol Cancer; 2008; 18(3):506-14. PubMed ID: 17868344
[TBL] [Abstract][Full Text] [Related]
52. Co-expression of stem cell genes CD133 and CD44 in colorectal cancers with early liver metastasis.
Huang X; Sheng Y; Guan M
Surg Oncol; 2012 Jun; 21(2):103-7. PubMed ID: 21764578
[TBL] [Abstract][Full Text] [Related]
53. Dystroglycan expression is frequently reduced in human breast and colon cancers and is associated with tumor progression.
Sgambato A; Migaldi M; Montanari M; Camerini A; Brancaccio A; Rossi G; Cangiano R; Losasso C; Capelli G; Trentini GP; Cittadini A
Am J Pathol; 2003 Mar; 162(3):849-60. PubMed ID: 12598319
[TBL] [Abstract][Full Text] [Related]
54. CD133 expression associated with poor prognosis in ovarian cancer.
Zhang J; Guo X; Chang DY; Rosen DG; Mercado-Uribe I; Liu J
Mod Pathol; 2012 Mar; 25(3):456-64. PubMed ID: 22080056
[TBL] [Abstract][Full Text] [Related]
55. Expression of CD133 in neuroendocrine neoplasms of the digestive tract: a detailed immunohistochemical analysis.
Mia-Jan K; Munkhdelger J; Lee MR; Ji SY; Kang TY; Choi E; Cho MY
Tohoku J Exp Med; 2013 Apr; 229(4):301-9. PubMed ID: 23615455
[TBL] [Abstract][Full Text] [Related]
56. Phenotypic subpopulations of metastatic colon cancer stem cells: genomic analysis.
Botchkina IL; Rowehl RA; Rivadeneira DE; Karpeh MS; Crawford H; Dufour A; Ju J; Wang Y; Leyfman Y; Botchkina GI
Cancer Genomics Proteomics; 2009; 6(1):19-29. PubMed ID: 19451087
[TBL] [Abstract][Full Text] [Related]
57. The relationship of CD133, histone deacetylase 1 and thrombospondin-1 in gastric cancer.
Eto S; Yoshikawa K; Shimada M; Higashijima J; Tokunaga T; Nakao T; Nishi M; Takasu C; Sato H; Kurita N
Anticancer Res; 2015 Apr; 35(4):2071-6. PubMed ID: 25862862
[TBL] [Abstract][Full Text] [Related]
58. CD133 expression is correlated with chemoresistance and early recurrence of gastric cancer.
Lee HH; Seo KJ; An CH; Kim JS; Jeon HM
J Surg Oncol; 2012 Dec; 106(8):999-1004. PubMed ID: 22674531
[TBL] [Abstract][Full Text] [Related]
59. Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer.
Hashimoto K; Aoyagi K; Isobe T; Kouhuji K; Shirouzu K
Gastric Cancer; 2014 Jan; 17(1):97-106. PubMed ID: 23558457
[TBL] [Abstract][Full Text] [Related]
60. CD133 immunohistochemical expression predicts progression and cancer-related death in renal cell carcinoma.
Costa WH; Rocha RM; Cunha IW; Fonseca FP; Guimaraes GC; Zequi Sde C
World J Urol; 2012 Aug; 30(4):553-8. PubMed ID: 21969131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]